ライフサイエンスコーパス: head and neck cancer

1 carcinoma (HNSCC) accounts for nearly 90% of head and neck cancer.

2 ighest for cervical cancer and oropharyngeal head and neck cancer.

3 of morbidity and mortality in patients with head and neck cancer.

4 carcinoma (HNSCC) is the most common form of head and neck cancer.

5 ive SELPs for viral mediated gene therapy of head and neck cancer.

6 ive side effects associated with therapy for head and neck cancer.

7 fective photosensitizer for PDT of resistant head and neck cancer.

8 therapeutic relevance of targeting CXCR7 in head and neck cancer.

9 diotherapy or combined chemoradiotherapy for head and neck cancer.

10 ypes other than lung, such as pancreatic and head and neck cancer.

11 atients with lymphoma, colorectal cancer, or head and neck cancer.

12 r the first time high expression of CXCR7 in head and neck cancer.

13 rapy alone in patients with locally advanced head and neck cancer.

14 ression in tumor biopsies from patients with head and neck cancer.

15 o target this pathway as a strategy to treat head and neck cancer.

16 advanced non-small-cell lung cancer, and in head and neck cancer.

17 ultidisciplinary management of patients with head and neck cancer.

18 processed meats and sweets for prevention of head and neck cancer.

19 t fully account for potency of E7 in causing head and neck cancer.

20 w that E7 is the dominant HPV oncoprotein in head and neck cancer.

21 emotherapy resistance in HA-CD44v3-activated head and neck cancer.

22 in and fluorouracil (PF) in locally advanced head and neck cancer.

23 benefit compared with PF in locally advanced head and neck cancer.

24 t chemotherapy for locally advanced squamous head and neck cancer.

25 ation therapy in patients with squamous cell head and neck cancer.

26 ue positively or negatively in patients with head and neck cancer.

27 different tumor models and in patients with head and neck cancer.

28 idisciplinary management of various types of head and neck cancer.

29 nidazole ((18)F-FMISO) dynamic PET (dPET) in head and neck cancer.

30 han patients with traditional, HPV-negative, head and neck cancer.

31 count from neck dissection in patients with head and neck cancer.

32 chemotherapy resistance in HA/CD44-activated head and neck cancer.

33 TNBC, gastric cancer, urothelial cancer, and head and neck cancer.

34 ledge toward the betterment of patients with head and neck cancer.

35 mography data of 1,019 patients with lung or head-and-neck cancer.

36 ognostic phenotype existing in both lung and head-and-neck cancer.

37 urrences (LR) and distant metastases (DM) in head-and-neck cancer.

38 the prevention and treatment of HPV-positive head and neck cancers.

39 ital cancers, including cervical cancer, and head and neck cancers.

40 significant toxicity during radiotherapy for head and neck cancers.

41 therapy response assessment using PET/CT for head and neck cancers.

42 inomas and many other tumors, including many head and neck cancers.

43 T/CT in the clinical workup of patients with head and neck cancers.

44 of death in patients with breast, lung, and head and neck cancers.

45 ependently associated with increased risk of head and neck cancers.

46 debilitating side effect of radiotherapy for head and neck cancers.

47 pes of cancer, including cervical, anal, and head and neck cancers.

48 e field of cancer stem cells with a focus on head and neck cancers.

49 erwent ECT for the treatment of non-melanoma head and neck cancers.

50 essor and a prognostic marker for human oral/head and neck cancers.

51 ese cell lines and was co-expressed in human head and neck cancers.

52 management of acute hemorrhage from advanced head and neck cancers.

53 ncreatic adenocarcinomas (PDA), prostate, or head and neck cancers.

54 erm increased risk of anogenital cancers and head and neck cancers.

55 the concomitant downregulation of rap1GAP in head and neck cancers.

56 log 2 (EZH2), a histone methyltransferase in head and neck cancers.

57 pregulation and poor prognosis in breast and head and neck cancers.

58 maviruses (HPV) cause certain anogenital and head and neck cancers.

59 o been implicated in the development of some head and neck cancers.

60 T cells from patients with breast, lung, and head and neck cancers.

61 ival only in T-cell-inflamed tumor models of head and neck cancers.

62 rolizumab as anticancer therapy for advanced head and neck cancers.

63 rculating biomarkers for cervical as well as head and neck cancers.

64 r human malignancies, including cervical and head and neck cancers.

65 ated tumors constitute a unique entity among head and neck cancers.

66 of all human cancers, including cervical and head-and-neck cancers.

67 and multiple cancers, including cervical and head-and-neck cancers.

68 cervical, vulvar, vaginal, penile, anal, and head-and-neck cancers.

69 esticular, ovarian, cervical, bladder, lung, head, and neck cancers.

70 adder carcinoma (3.3%), glioblastoma (4.4%), head and neck cancer (1.0%), low-grade glioma (1.5%), lu

71 ostate cancer, 28.6 versus 35.5 versus 39.4; head and neck cancer, 21.1 versus 29.4 versus 40.2; and

72 , 36.8% to 46.4%), followed by patients with head and neck cancer (40.8%; 95% CI, 28.5% to 53.0%).

73 stoma (20.5%), colorectal cancer (7.7%), and head and neck cancer (6.7%).

74 In head and neck cancer, a change in (18)F-FLT uptake early

75 wth inhibition in a mouse xenograft model of head and neck cancer, a type of the disease which often

76 HPV-negative head and neck cancers abundantly express EGFR, and the m

77 lanoma, non-small cell lung, esophageal, and head and neck cancer, among others, are intrinsically re

78 status are routinely obtained in the care of head and neck cancer and are clearly associated with pat

79 status are routinely obtained in the care of head and neck cancer and are clearly associated with pat

80 nd p107 act together to efficiently suppress head and neck cancer and are, therefore, highly relevant

81 DH activity as well as invasive potential in head and neck cancer and breast cancer cells.

82 o monitor the early response to treatment of head and neck cancer and evaluated the association betwe

83 alized solid tumors including breast cancer, head and neck cancer and GIST.

84 the mainstay of treatment for patients with head and neck cancer and has traditionally involved a st

85 recently reported the somatic alterations in head and neck cancer and have highlighted the distinct g

86 Nude rats bearing human head and neck cancer and non-small cell lung cancer (NSC

87 o patients carrying BRCA mutations: one with head and neck cancer and one with ovarian cancer.

88 s between "oral clocks" and diseases such as head and neck cancer and Sjogren's syndrome.

89 n play an essential role in the treatment of head and neck cancer and the care of patients and their

90 ion to these two genes, Ubiquitin C (UBC) in head and neck cancer and Transferrin receptor (TFRC) and

91 35 patients who had undergone irradiation of head and neck cancer and who had subsequent C1 or C2 les

92 R-targeted therapies in lung, colorectal and head and neck cancers and discuss therapeutic strategies

93 distinct biology of recurrent and metastatic head and neck cancers and review implementation of preci

94 distinct biology of recurrent and metastatic head and neck cancers and review implementation of preci

95 ntral part in the diagnosis and treatment of head and neck cancer, and building surgical capacity, wh

96 Patients with locally advanced head and neck cancer, and who had not previously undergo

97 n many human cancers, including cervical and head and neck cancers, and is responsible for the annual

98 s and being overweight before diagnosis with head and neck cancer are associated with a better progno

99 Personal View, several important studies in head and neck cancer are reviewed, with focus on issues

100 Other HPV-associated anogenital and head and neck cancers are predicted to afflict another 7

101 pRb/p107-deficient mice developed head and neck cancer as frequently as do HPV-16 E7 trans

102 nce trend and pathogenesis of HPV-associated head-and-neck cancers as well as current treatment modal

103 sease sites discussed in this Review include head and neck cancer, breast cancer, sarcoma, gastrointe

104 tial targets for therapeutic intervention in head and neck cancer but also may aid in the identificat

105 nd scale, can not only address the burden of head and neck cancer, but also create a platform for beg

106 ng efforts have elucidated relevant genes in head and neck cancer, but HPV-related tumors have consis

107 ompeting mortality) is an important event in head and neck cancer, but studies identifying predictors

108 as been reported in HPV-related cervical and head and neck cancers, but such data have not been avail

109 pipe smoking are considered risk factors for head and neck cancers, but the magnitude of effect estim

110 d chemoradiation in resistant and aggressive head and neck cancer by 100-fold in vitro and 17-fold in

111 coCEST) to image unlabeled glucose uptake in head and neck cancer by using a clinical 3T magnetic res

112 urative treatment for patients with advanced head and neck cancer can be associated with many side-ef

113 We conclude that glucoCEST images of head and neck cancer can be obtained with a clinical 3T

114 Radiation therapy for head and neck cancer can result in extensive damage to n

115 associated with outcome when considering all head and neck cancer cases (HR for serology,0.49; 95% CI

116 e hamster ovary cells and the UMSCC11B human head and neck cancer cell line protected EGFR from cispl

117 We also show that head and neck cancer cell lines with loss-of-function mu

118 highly correlated with cytotoxicity in seven head and neck cancer cell lines.

119 ay be distinct between high and low invasive head and neck cancer cells and between CSCs and non-SCCs

120 ied to an untargeted metabolomic analysis of head and neck cancer cells and stem-like cancer cells.

121 plied to analysis of targeted metabolites in head and neck cancer cells as well as cancer stem-like c

122 PNBs were generated in vivo in head and neck cancer cells by systemically targeting tum

123 Conversely, whereas p53 wild-type HN30 head and neck cancer cells did show sensitization to rad

124 etion of the angiogenic chemokine CXCL1 from head and neck cancer cells in vitro, thus acting here as

125 provide evidence that Hpa2 overexpression in head and neck cancer cells markedly reduces tumor growth

126 Here we show that cisplatin treatment of head and neck cancer cells results in nuclear transport

127 Da eIF2Bepsilon led to increased survival of head and neck cancer cells under hypoxia, providing evid

128 activated protein kinase (AMPK) signaling in head and neck cancer cells.

129 stem cells, but did not accelerate growth of head and neck cancer cells.

130 erapy (PDT) is a promising approach to treat head and neck cancer cells.

131 we performed RNA-Seq of normoxic and hypoxic head and neck cancer cells.

132 ited little toxicity and biocompatibility in head and neck cancer cells.

133 opharyngeal carcinoma (NPC) is an aggressive head and neck cancer characterized by Epstein-Barr virus

134 using novel agents will hopefully streamline head and neck cancer chemoprevention research.

135 itantly, the incidence of tobacco-associated head and neck cancers decreased for elderly patients (la

136 t inhibitors are relatively inefficacious in head and neck cancers, despite an abundance of genetic a

137 ogression of human cancer, but their role in head and neck cancer development and progression is not

138 omavirus (HPV) sequences and that HPV-driven head and neck cancers display distinct biological and cl

139 ents who have undergone previous surgery for head and neck cancer do not benefit from non-platinum ch

140 nt with animal studies in osteoarthritis and head and neck cancer, early blockade of NGF reduced weig

141 re often found in subregions of cervical and head and neck cancers, enable HPV-positive cancer cells

142 By using pooled data from the International Head and Neck Cancer Epidemiology (INHANCE) Consortium (

143 ses and 8,375 controls) in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium,

144 Using data from the International Head and Neck Cancer Epidemiology Consortium, the author

145 dies revealed that HPV-positive cervical and head-and-neck cancers exhibited higher rates of hA3 muta

146 Head and neck cancer, for which the diagnosis and treatm

147 cilitated accurate subtype identification in head and neck cancer from gene expression data in both f

148 alysis with oropharyngeal cancer data from a head and neck cancer genome-wide association study (GWAS

149 validation, replicated significantly in the head and neck cancer GWAS limited to HPV-seropositive ca

150 Methods to reduce SSI in patients with head and neck cancer have been intensely researched, yie

151 and its interaction with the host genome in head and neck cancers have not been comprehensively desc

152 den of oral HPV infection and HPV-associated head and neck cancer (HNC) among HIV-infected individual

153 ogression of cancer, but prospective data on head and neck cancer (HNC) and oesophagus cancer are lim

154 Patients with head and neck cancer (HNC) are at high risk of death res

155 revious studies on smokeless tobacco use and head and neck cancer (HNC) have found inconsistent and o

156 Head and neck cancer (HNC) is the seventh most common ca

157 Head and neck cancer (HNC) is the seventh most-common ty

158 r Network guidelines recommend patients with head and neck cancer (HNC) receive treatment at centers

159 with human papillomavirus (HPV+)-associated head and neck cancer (HNC) show significantly improved s

160 mendations on the management of adults after head and neck cancer (HNC) treatment, focusing on survei

161 In patients with head and neck cancer (HNC), the surrounding normal saliv

162 and cancer-associated fibroblasts (CAFs) in head and neck cancer (HNC), thereby promoting tumorigene

163 and Ca(2+) flux on TIL effector function in head and neck cancer (HNC).

164 bilitating toxicity of chemoradiotherapy for head and neck cancer (HNC).

165 , but less is known about HPV integration in head and neck cancer (HNC).

166 therapy and subsequent chemoradiotherapy of head and neck cancer (HNC).

167 in various types of human cancers, including head and neck cancer (HNC).

168 Many cancer types, including head and neck cancers (HNC), express programmed death li

169 receptor (EGFR) is an established target in head-and-neck cancer (HNC), resistance to EGFR-targeted

170 d in clinical specimens of glioblastomas and head and neck cancers (HNCs) and is required for EGFR-st

171 ed by induction of oxidative stress in human head and neck cancer (HNSCC) cells.

172 eted antibody cetuximab is effective against head and neck cancer (HNSCC), but in only 15% to 20% of

173 ciation between use of smokeless tobacco and head and neck cancer in 11 US case-control studies.

174 on the management of locoregionally confined head and neck cancer in elderly patients and propose a p

175 Head and neck cancer in elderly patients represents a ma

176 losses due to the morbidity and mortality of head and neck cancer in India, Pakistan, and Bangladesh

177 ion regarding the morbidity and mortality of head and neck cancer in India, Pakistan, and Bangladesh,

178 In head and neck cancer in particular, proton beam therapy

179 stimate total economic welfare losses due to head and neck cancer in the aforementioned countries in

180 population-based study of 1054 patients with head and neck cancer in the greater Boston, Massachusett

181 population-based study of 1054 patients with head and neck cancer in the greater Boston, Massachusett

182 d carborane derivatives for the treatment of head and neck cancer in the hamster cheek pouch oral can

183 e estimate of economic welfare losses due to head and neck cancer in the three studied countries is U

184 family correlates with its ability to induce head and neck cancers in mice.

185 hageal, endometrial, cervical, prostate, and head and neck cancers, in addition to sarcoma, lymphoma,

186 The current standard of care for head and neck cancer includes surgical resection of the

187 eviewing immunological principles related to head and neck cancer, including the concept of cancer im

188 Among these cancers, HPV-associated head-and-neck cancers, inclusive of oropharyngeal squamo

189 Odds ratios for head and neck cancer increase with greater cigarette and

190 hibited a close association in patients with head and neck cancer, indicating that the surrounding Tr

191 in human patients following radiotherapy for head and neck cancer is a common and significant problem

192 Head and neck cancer is a leading cause of cancer-relate

193 CONCLUSION Competing mortality in advanced head and neck cancer is associated with several demograp

194 Head and neck cancer is becoming more common, and surviv

195 Head and neck cancer is one of the most prevalent cancer

196 Head and neck cancer is the fifth most common cancer wor

197 th chemoradiotherapy alone for patients with head and neck cancer is unclear.

198 nt measure for predicting patient outcome in head and neck cancer is unknown.

199 fe issues and meet the needs of survivors of head and neck cancer is urgently required.

200 Recurrent and/or metastatic head and neck cancer is usually incurable.

201 Importance: Recurrent and/or metastatic head and neck cancer is usually incurable.

202 chemoradiotherapy (CCRT) in locally advanced head and neck cancer (LA-HNC) and correlate outcomes wit

203 for patients with resected locally advanced head and neck cancer (LAHNC) with negative surgical marg

204 randomized trials in locoregionally advanced head and neck cancers (LAHNCs).

205 Epigenetic correlates of the head and neck cancer may illuminate its pathogenic roots

206 l or endodermal origins such as lung cancer, head and neck cancer, melanoma, and hepatocellular carci

207 esistance to EGFR inhibition in HPV-negative head and neck cancer might help identify novel and activ

208 The heterotopic syngeneic murine head and neck cancer model (mEER) caused systemic inflam

209 ies which have contributed to discovery of a head and neck cancer mutation association.

210 atients with primary breast cancer (n = 13), head and neck cancer (n = 10), and lymphoma (n = 7) were

211 tients), 2 colorectal cancer (n = 96), and 4 head and neck cancer (n = 194).

212 intravenously administered to patients with head and neck cancer (n = 4) scheduled for surgery 5-7 d

213 er central nervous system disorder (n = 51), head and neck cancer (n = 47), and other malignancy (n =

214 = 16), breast (n = 7), stomach (n = 2), and head and neck cancers (n = 3), as well as unknown primar

215 aches, although promising, for patients with head and neck cancer need to be demonstrated in prospect

216 In a multivariable model, having lung/head and neck cancer (odds ratio [OR], 1.74; 95% CI, 1.2

217 cterium chelonae infection in a patient with head and neck cancer on salvage chemotherapy, including

218 ed with care-as-usual (CAU) in patients with head and neck cancer or lung cancer who have psychologic

219 n improving distress levels of patients with head and neck cancer or lung cancer.

220 ing from therapeutic radiation treatment for head and neck cancers or from the autoimmune disease Sjo

221 e association of diet and weight status with head and neck cancer outcomes.

222 n cervical carcinoma and a growing number of head-and-neck cancers, p53 is degraded by the viral onco

223 ctional characteristics of acute and chronic head and neck cancer pain in humans.

224 ly, snuff use was positively associated with head and neck cancer, particularly for cancers of the or

225 miRNAs and their target mRNAs contribute to head and neck cancer pathogenesis and progression.

226 etermine the clinical relevance, a cohort of head and neck cancer patient biopsies was examined for p

227 Young white women may be a new, emerging head and neck cancer patient population.

228 ression correlates with enhanced survival of head and neck cancer patients (p < 0.0000542), indicatin

229 erative therapy is a promising treatment for head and neck cancer patients that suffer from chronic d

230 Head and neck cancer patients treated by radiation commo

231 ortantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-base

232 ategy to preserve salivary gland function in head and neck cancer patients undergoing radiotherapy.

233 One hundred twenty head and neck cancer patients underwent 0- to 30-min (18

234 xists for salivary hypofunction in surviving head and neck cancer patients with Radiation Therapy Onc

235 In head and neck cancer patients, Hpa2 expression was marke

236 y inactivating GRIM-19 mutations in a set of head and neck cancer patients.

237 ection of bony metastases in heightened-risk head and neck cancer patients.

238 radiation response assessment in unselected head and neck cancer patients.

239 ies addressing supportive care issues facing head and neck cancer patients.

240 eproducibility of multiparametric imaging in head and neck cancer patients.

241 reclinical setting and in clinical trials in head and neck cancer patients.

242 nalization of chemo-radiation treatments for head-and-neck cancer patients from different risk groups

243 c power in independent data sets of lung and head-and-neck cancer patients, many of which were not id

244 We identified 638 participants with incident head and neck cancers (patients; 180 oral cancers, 135 o

245 Head and neck cancers positive for human papillomavirus

246 Head and neck cancers positive for human papillomavirus

247 d colorectal cancers and fentanyl family for head and neck cancers (PR, 1.39; 95% CI, 1.19 to 1.62) c

248 y identified causative agent for a subset of head and neck cancers, primarily in the oropharynx, and

249 tterns and weight status are associated with head and neck cancer prognosis.

250 y, STAT3 phosphorylation was associated with head and neck cancer progression, EGFR phosphorylation,

251 oncogene-tumor suppressor axis to understand head and neck cancer progression.

252 genes correlates with prostate, breast, and head and neck cancer recurrence.

253 nce, morbidity and mortality associated with head and neck cancer remain high.

254 Recurrent/metastatic head and neck cancer remains a devastating disease with

255 Radiation therapy for head and neck cancer results in severe secondary side-ef

256 Head and neck cancer risk was elevated for those who rep

257 e whether HPV antibodies are associated with head and neck cancer risk when measured in prediagnostic

258 are commonly methylated and downregulated in head and neck cancers (SEPT9, SLC5A8, FUSSEL18, EBF3, an

259 cervical (SIR, 1.5), penile (SIR, 8.2), and head and neck cancer (SIR, 2.8), including subsites of h

260 ed with improved patient survival across all head and neck cancer sites: HR for oropharynx cancer, 0.

261 e Questionnaire-Core 30 (QLQ-C30), the EORTC head and neck cancer-specific module (EORTC QLQ-H&N35),

262 ation is frequently reported in cervical and head and neck cancer specimens.

263 Interestingly, HPV-positive cervical and head-and-neck cancer specimens were recently shown to ha

264 cultures of collectively invading breast and head and neck cancer spheroids, here we identify hypoxia

265 hod for in vitro culture of undifferentiated head and neck cancer stem cells under low attachment con

266 as examined by sphere formation of colon and head and neck cancer stem cells under nonadherent condit

267 known about functional interactions between head and neck cancer stem-like cells (CSC) and surroundi

268 sponse, which are distinct from HPV-negative head and neck cancers, suggesting that virus-associated

269 Head and neck cancer surgery is often a complex multi-st

270 As the population of head and neck cancer survivors increases, it has become

271 Although it has long been recognized that head and neck cancer therapy results in significant acut

272 Herein, we review late effects of head and neck cancer therapy, highlighting recent advanc

273 ng and alcohol consumption increase risk for head and neck cancers, there have been few attempts to m

274 Nurses influence treatment for head and neck cancer through symptom management and toba

275 lay an important role in chemosensitivity of head and neck cancers through ubiquitination of NFkappaB

276 The complete MET gene was sequenced in 66 head and neck cancer tissue samples and eight cell lines

277 sents a possible biomarker of sensitivity of head and neck cancers to cell killing after PDT.

278 research suggests that nurses can influence head and neck cancer treatment through emphasis on sympt

279 ortant implications for our understanding of head and neck cancer tumorigenesis and for the use of ta

280 aryngeal cancer, cervical cancer, and HPV(+) head and neck cancer tumors.

281 epigenetically activated proto-oncogenes in head and neck cancer tumors.

282 me time, the molecular profiles of many rare head and neck cancer types are unknown.

283 Forty-eight patients with head and neck cancer underwent (18)F-FLT PET/CT before a

284 th biopsy-proven lymphoma, breast cancer, or head and neck cancer underwent (18)F-ISO-1 PET.

285 referred for primary staging or restaging of head and neck cancer underwent sequential whole-body (18

286 In clinical specimens of head and neck cancer, we found that coamplification of B

287 ative treatments for patients with recurrent head and neck cancer, we reviewed the evidence on common

288 y untreated, non-metastatic, newly diagnosed head and neck cancer were eligible.

289 HPV-positive head and neck cancers were more heavily infiltrated by r

290 marrow failure, acute myeloid leukemia, and head and neck cancers, whereas BS is characterized by gr

291 outcomes for colon, lung, hepatobiliary, and head and neck cancer, which are predominantly diseases o

292 therapeutic use from inhibiting Aurora A in head and neck cancers, which overexpress BMI1.

293 sue of appropriately selecting patients with head and neck cancer who can benefit from CTX in combina

294 l study of 542 patients with newly diagnosed head and neck cancer who completed food-frequency questi

295 h metastatic lung, colorectal, pancreatic or head and neck cancers who initially benefit from epiderm

296 oma, lung nonsquamous, squamous cell lung or head and neck cancers who were treated with the approved

297 eck cancer (SIR, 2.8), including subsites of head and neck cancer with confirmed HPV association (SIR

298 We profiled a cohort of 279 head and neck cancers with next generation RNA and DNA s

299 r detecting bony metastases in patients with head and neck cancers, with similar sensitivity to (18)F

300 Using a patient-derived CXCR7-expressing head and neck cancer xenograft model in nude mice, tumor